Project Grant W81XWH1910195

This federal Cooperative Agreement award, titled "SPECTRAL FLOW CYTOMETRY IDENTIFIES NEW IMMUNE SIGNATURES THAT PROVIDE PERSONALIZED ALS RISK AND PROGRESSION BIOMARKERS AND THERAPEUTIC TARGETS", is funded by the Agency for Toxic Substances and Disease Registry (ATSDR) under the State Capacity Building Program (CFDA 93.240). The $500,000.00 award, effective September 30, 2025, supports research conducted by the Regents of the University of Michigan to identify new biomarkers and...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,153 to Alelopharma Inc. to develop an ultra-sensitive molecular diagnostic platform for detecting EML4-ALK gene fusions in non-small cell lung cancer patients. The objective is to create a blood-based "liquid biopsy" test that can accurately identify ALK-positive lesions, which respond well to targeted cancer therapies, without the need for tissue re-biopsy....

This federal Project Grant award of $704,431.23 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to Meso Scale Diagnostics LLC, doing business as Meso Scale Discovery, supports the development of ultrasensitive plasma and cerebrospinal fluid immunoassays to enable clinical trials for amyotrophic lateral sclerosis (ALS). As a for-profit limited liability company specializing in assay development, laboratory testing, and related products for biomedical...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

This Project Grant award of $532,381 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research into the pathogenic mechanisms of the KIF5A gene mutation associated with amyotrophic lateral sclerosis (ALS). The key objectives of this 5-year research project are to: 1) determine the gain-of-function effects of the ALS-associated KIF5A exon 27 skipping variant...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,499,212 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Aquinnah Pharmaceuticals, Inc. The grant supports the development of a novel oral, brain penetrant therapeutic to slow and potentially reverse the progression of Amyotrophic Lateral Sclerosis (ALS). The key product being delivered is an innovative new clinical drug candidate designed to...

This Project Grant award of $374,349 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development and optimization of a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The goal is to create a mouse model that accurately recapitulates the human disease spectrum by incorporating an acetylation-mimicking...

The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $404,058 project grant to the Regents of the University of Minnesota to support a novel approach to restore functional TDP43 for the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The goal of the project is to identify small molecule compounds that can stabilize functional, multimerized forms of the TDP43 protein in order to restore its normal RNA...

This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop neuronal exosome-based biomarkers for the diagnosis and disease progression of amyotrophic lateral sclerosis (ALS). The total award amount is $1,181,251.00, with a performance period from April 15, 2025 to April 14, 2028. The principal investigator for this grant is the University of California, Los Angeles (UCLA), which has a...

The Research Foundation for the State University of New York (RF-SUNY) was awarded $768,825 under the Military Medical Research and Development grant program (CFDA 12.420) by the Defense Health Agency to test RNA aptamers in the SOD1 G93A ALS mouse model from September 1, 2023 to August 31, 2025. This funding will support RF-SUNY's research at the University at Albany to investigate medical solutions for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, by exploring the...